Fidelity Investments’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.17B | Sell |
1,518,192
-801,374
| -35% | -$614M | 0.06% | 252 |
|
|
2025
Q4 | $1.79B | Buy |
2,319,566
+383,731
| +20% | +$261M | 0.09% | 175 |
|
|
2025
Q3 | $1.09B | Sell |
1,935,835
-1,391,216
| -42% | -$787M | 0.06% | 266 |
|
|
2025
Q2 | $1.75B | Sell |
3,327,051
-4,271,533
| -56% | -$2.38B | 0.1% | 161 |
|
|
2025
Q1 | $4.82B | Sell |
7,598,584
-600,995
| -7% | -$413M | 0.31% | 39 |
|
|
2024
Q4 | $5.84B | Sell |
8,199,579
-2,163,122
| -21% | -$1.82B | 0.35% | 32 |
|
|
2024
Q3 | $10.9B | Sell |
10,362,701
-286,773
| -3% | -$319M | 0.66% | 18 |
|
|
2024
Q2 | $11.2B | Sell |
10,649,474
-144,598
| -1% | -$140M | 0.72% | 16 |
|
|
2024
Q1 | $10.4B | Buy |
10,794,072
+476,657
| +5% | +$453M | 0.7% | 18 |
|
|
2023
Q4 | $9.06B | Buy |
10,317,415
+476,523
| +5% | +$392M | 0.7% | 16 |
|
|
2023
Q3 | $8.1B | Buy |
9,840,892
+669,517
| +7% | +$526M | 0.7% | 15 |
|
|
2023
Q2 | $6.59B | Sell |
9,171,375
-268,721
| -3% | -$207M | 0.55% | 22 |
|
|
2023
Q1 | $7.76B | Sell |
9,440,096
-1,656,895
| -15% | -$1.25B | 0.71% | 15 |
|
|
2022
Q4 | $8.01B | Buy |
11,096,991
+287,245
| +3% | +$212M | 0.8% | 15 |
|
|
2022
Q3 | $7.45B | Buy |
10,809,746
+633,547
| +6% | +$399M | 0.78% | 14 |
|
|
2022
Q2 | $6.02B | Buy |
10,176,199
+193,175
| +2% | +$126M | 0.6% | 20 |
|
|
2022
Q1 | $6.97B | Sell |
9,983,024
-79,943
| -0.8% | -$50.6M | 0.56% | 21 |
|
|
2021
Q4 | $6.35B | Sell |
10,062,967
-1,004,984
| -9% | -$618M | 0.47% | 28 |
|
|
2021
Q3 | $6.7B | Buy |
11,067,951
+157,257
| +1% | +$97.6M | 0.53% | 25 |
|
|
2021
Q2 | $6.09B | Sell |
10,910,694
-25,295
| -0.2% | -$12.8M | 0.48% | 29 |
|
|
2021
Q1 | $5.17B | Sell |
10,935,989
-545,585
| -5% | -$266M | 0.44% | 33 |
|
|
2020
Q4 | $5.55B | Sell |
11,481,574
-1,236,734
| -10% | -$668M | 0.49% | 25 |
|
|
2020
Q3 | $7.12B | Buy |
12,718,308
+254,828
| +2% | +$155M | 0.72% | 17 |
|
|
2020
Q2 | $7.77B | Buy |
12,463,480
+3,999,170
| +47% | +$2.27B | 0.85% | 16 |
|
|
2020
Q1 | $4.13B | Buy |
8,464,310
+5,238,483
| +162% | +$2.16B | 0.57% | 21 |
|
|
2019
Q4 | $1.21B | Buy |
3,225,827
+492,339
| +18% | +$166M | 0.13% | 146 |
|
|
2019
Q3 | $758M | Sell |
2,733,488
-462,308
| -14% | -$137M | 0.09% | 214 |
|
|
2019
Q2 | $1B | Sell |
3,195,796
-1,227,209
| -28% | -$409M | 0.12% | 169 |
|
|
2019
Q1 | $1.82B | Sell |
4,423,005
-924,371
| -17% | -$381M | 0.22% | 82 |
|
|
2018
Q4 | $2B | Buy |
5,347,376
+330,875
| +7% | +$121M | 0.27% | 66 |
|
|
2018
Q3 | $2.03B | Buy |
5,016,501
+728,104
| +17% | +$277M | 0.23% | 78 |
|
|
2018
Q2 | $1.48B | Sell |
4,288,397
-895,620
| -17% | -$280M | 0.17% | 105 |
|
|
2018
Q1 | $1.79B | Sell |
5,184,017
-445,322
| -8% | -$155M | 0.21% | 96 |
|
|
2017
Q4 | $2.12B | Sell |
5,629,339
-1,362,383
| -19% | -$552M | 0.25% | 70 |
|
|
2017
Q3 | $3.13B | Sell |
6,991,722
-48,162
| -0.7% | -$22.9M | 0.38% | 39 |
|
|
2017
Q2 | $3.46B | Buy |
7,039,884
+416,192
| +6% | +$182M | 0.43% | 34 |
|
|
2017
Q1 | $2.57B | Sell |
6,623,692
-1,200,634
| -15% | -$445M | 0.33% | 55 |
|
|
2016
Q4 | $2.87B | Sell |
7,824,326
-1,310,024
| -14% | -$498M | 0.38% | 41 |
|
|
2016
Q3 | $3.67B | Sell |
9,134,350
-282,486
| -3% | -$113M | 0.49% | 32 |
|
|
2016
Q2 | $3.29B | Buy |
9,416,836
+795,283
| +9% | +$306M | 0.45% | 41 |
|
|
2016
Q1 | $3.11B | Buy |
8,621,553
+2,398,461
| +39% | +$988M | 0.43% | 40 |
|
|
2015
Q4 | $3.38B | Buy |
6,223,092
+613,071
| +11% | +$332M | 0.45% | 36 |
|
|
2015
Q3 | $2.61B | Sell |
5,610,021
-322,126
| -5% | -$173M | 0.37% | 45 |
|
|
2015
Q2 | $3.03B | Sell |
5,932,147
-78,523
| -1% | -$38.3M | 0.39% | 37 |
|
|
2015
Q1 | $2.71B | Sell |
6,010,670
-676,422
| -10% | -$287M | 0.35% | 47 |
|
|
2014
Q4 | $2.74B | Buy |
6,687,092
+719,663
| +12% | +$283M | 0.36% | 44 |
|
|
2014
Q3 | $2.15B | Buy |
5,967,429
+686,906
| +13% | +$230M | 0.29% | 66 |
|
|
2014
Q2 | $1.49B | Sell |
5,280,523
-462,512
| -8% | -$137M | 0.2% | 106 |
|
|
2014
Q1 | $1.72B | Sell |
5,743,035
-1,500,348
| -21% | -$462M | 0.24% | 83 |
|
|
2013
Q4 | $1.99B | Sell |
7,243,383
-1,710,715
| -19% | -$492M | 0.28% | 66 |
|
|
2013
Q3 | $2.8B | Sell |
8,954,098
-1,344,261
| -13% | -$354M | 0.43% | 39 |
|
|
2013
Q2 | $2.32B | Buy |
+10,298,359
| New | +$2.4B | 0.38% | 47 |
|
Other funds holding REGN
VCM
N
Fidelity Investments's REGN Position: Q1 2026 in Review
Fidelity Investments reduced its Regeneron Pharmaceuticals (REGN) stake by 35% in Q1 2026, selling an estimated $614M and leaving 1,518,192 shares worth $1.17B. The position accounts for 0.06% of the portfolio, ranked #252.
Fidelity Investments first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.2B in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Fidelity Investments held 1,518,192 shares of Regeneron Pharmaceuticals worth $1.17B as of Q1 2026.
- Fidelity Investments sold 801,374 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $614M.
- Regeneron Pharmaceuticals made up 0.06% of Fidelity Investments's portfolio in Q1 2026, its #252 holding.
- Fidelity Investments first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Fidelity Investments's Regeneron Pharmaceuticals position peaked at $11.2B in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.